Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SymITA: Switch to DRV/COB/FTC/TAF From Integrase Containing Regimens to Evaluate Changes in Tolerability/Adherence

NCT04240210 is registered in ClinicalTrials.gov with Midland Research Group, Inc. as lead sponsor.

NCT NCT04240210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04240210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SymITA: Switch to DRV/COB/FTC/TAF From Integrase Containing Regimens to Evaluate Changes in Tolerability/Adherence
Lead sponsor
Midland Research Group, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
September 17, 2019
Completion date
December 1, 2021
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus